| This is the talk page for discussing improvements to the Patrick A. Baeuerle article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
| This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page. |
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||
| ||||||||||||||||||||||||
Controversial chapter in Prof. Baeuerle's life seems to be missing
Prof. Baeuerle was in the supervisory board (http://web.archive.org/web/20060622163024/http://www.tegenero.com/about_us/supervisory_board/index_1150.php) of the pharmaceutical research company TeGenero which later went bankrupt (https://en.wikipedia.org/wiki/TeGenero). This company developed the product TGN1412 (https://en.wikipedia.org/wiki/TGN1412) which caused life-threatening multiple organ failure in six human subjects which tested the product (http://www.i-sis.org.uk/LDTC.php)(http://www.theguardian.com/society/2007/feb/17/health.lifeandhealth). Whoever74 (talk) 07:27, 17 January 2016 (UTC)